JP5978216B2 - テオフィリンとフェブキソスタットの併用療法のための方法 - Google Patents

テオフィリンとフェブキソスタットの併用療法のための方法 Download PDF

Info

Publication number
JP5978216B2
JP5978216B2 JP2013528294A JP2013528294A JP5978216B2 JP 5978216 B2 JP5978216 B2 JP 5978216B2 JP 2013528294 A JP2013528294 A JP 2013528294A JP 2013528294 A JP2013528294 A JP 2013528294A JP 5978216 B2 JP5978216 B2 JP 5978216B2
Authority
JP
Japan
Prior art keywords
theophylline
xanthine oxidoreductase
patient
administration
oxidoreductase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013528294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539747A (ja
JP2013539747A5 (enExample
Inventor
グナワルダナ，ラノー
ナイク，ヒマンシユ
ツアイ，マツクス
Original Assignee
タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド
タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5978216(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド, タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド filed Critical タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド
Publication of JP2013539747A publication Critical patent/JP2013539747A/ja
Publication of JP2013539747A5 publication Critical patent/JP2013539747A5/ja
Application granted granted Critical
Publication of JP5978216B2 publication Critical patent/JP5978216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013528294A 2010-09-10 2011-09-08 テオフィリンとフェブキソスタットの併用療法のための方法 Active JP5978216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38148210P 2010-09-10 2010-09-10
US61/381,482 2010-09-10
PCT/US2011/050870 WO2012033941A1 (en) 2010-09-10 2011-09-08 Methods for concomitant treatment of theophylline and febuxostat

Publications (3)

Publication Number Publication Date
JP2013539747A JP2013539747A (ja) 2013-10-28
JP2013539747A5 JP2013539747A5 (enExample) 2014-10-23
JP5978216B2 true JP5978216B2 (ja) 2016-08-24

Family

ID=44653592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013528294A Active JP5978216B2 (ja) 2010-09-10 2011-09-08 テオフィリンとフェブキソスタットの併用療法のための方法

Country Status (11)

Country Link
US (3) US9107912B2 (enExample)
EP (1) EP2613780B1 (enExample)
JP (1) JP5978216B2 (enExample)
KR (1) KR101797936B1 (enExample)
CN (1) CN103298466B (enExample)
AU (1) AU2011299153B2 (enExample)
BR (1) BR112013005792A8 (enExample)
CA (1) CA2812034C (enExample)
ES (1) ES2532210T3 (enExample)
RU (1) RU2013109380A (enExample)
WO (1) WO2012033941A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121995A2 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
CN103862983B (zh) * 2012-12-12 2016-12-21 石狮市冠鑫反光材料有限公司 3d立体画制作工艺
ES2552706B1 (es) * 2014-05-29 2016-09-13 Universitat De Les Illes Balears La teobromina y sus derivados para el tratamiento o prevenciónde la litiasis renal
KR102133290B1 (ko) * 2018-10-23 2020-07-13 연세대학교 산학협력단 결핵의 예방 또는 치료용 조성물
CN120271528B (zh) * 2025-04-08 2025-08-22 中国食品药品检定研究院 一种非布司他与苦豆碱共无定型物及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4296122A (en) 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
DE2707268A1 (de) 1977-02-19 1978-08-31 Hoechst Ag Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung
DE2707270A1 (de) 1977-02-19 1978-08-24 Hoechst Ag Pyrazolo-diazepine und verfahren zu ihrer herstellung
DE2707269A1 (de) 1977-02-19 1978-08-24 Hoechst Ag Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung
DE2727802A1 (de) 1977-06-21 1979-04-19 Hoechst Ag Sulfamoyl-arylketone und verfahren zu ihrer herstellung
JPS5936919B2 (ja) 1978-10-14 1984-09-06 日本新薬株式会社 インド−ル誘導体
DE3112116A1 (de) * 1981-03-27 1982-11-04 Mundipharma GmbH, 6250 Limburg "arzneimittel"
US4510322A (en) 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
DE3232922A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Sulfamoylbenzophenon-derivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
US4632930A (en) 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JPH0366669A (ja) 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
CA2115442C (en) 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist
US5358961A (en) 1991-11-30 1994-10-25 Jin Ro Limited Pyrrolidine derivatives
JP2706037B2 (ja) 1993-04-13 1998-01-28 帝人株式会社 シアノ化合物およびその製造方法
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07242694A (ja) 1994-02-28 1995-09-19 Yamasa Shoyu Co Ltd トリアゾロプリンヌクレオシド誘導体及び該誘導体を製造するのに有用な合成中間体
US5770601A (en) 1994-08-17 1998-06-23 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US5514681A (en) 1994-08-17 1996-05-07 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US6037344A (en) 1994-08-17 2000-03-14 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
AUPM835394A0 (en) 1994-09-23 1994-10-13 King, Michael G. Dr. Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need
CA2213420A1 (en) 1995-02-21 1996-08-29 Kazuki Endo Purine compounds and xanthine oxidase inhibitors
US6084147A (en) 1995-03-17 2000-07-04 Studsvik, Inc. Pyrolytic decomposition of organic wastes
US5843969A (en) 1995-04-07 1998-12-01 Teijin Limited Protecting agent for organ or tissue
JPH1045773A (ja) 1996-08-07 1998-02-17 Daicel Chem Ind Ltd リン含有化合物およびその製造方法
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US5965625A (en) 1997-03-21 1999-10-12 King; Michael Glenn Compositions and methods for the control of smoking
AU1520699A (en) 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
JPH11140086A (ja) 1997-11-07 1999-05-25 Yamasa Shoyu Co Ltd ４−置換−１Ｈ−６−オキソピラゾロ［３，４−ｄ］ピリミジン化合物及びキサンチンオキシダーゼ阻害剤
PL200710B1 (pl) 1998-06-19 2009-01-30 Teijin Pharma Ltd Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US6281222B1 (en) 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
ECSP993280A (es) 1999-12-17 2001-07-27 Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos
EP1317258B1 (en) 2000-06-28 2009-02-11 Merck & Co., Inc. Use of allopurinol for the treatment of hypertension
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
WO2002085380A1 (en) 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
CA2444347A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Method for treating gout and binding uric acid
CA2463441A1 (en) 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
DK1471065T3 (da) 2002-01-28 2008-03-25 Fuji Yakuhin Co Ltd Hidtil ukendt 1,2,4-triazolforbindelse
ES2505690T3 (es) 2002-03-28 2014-10-10 Teijin Pharma Limited Preparación sólida que contiene una forma única de cristal de un derivado de ácido tiazolcarboxílico
US20060040945A1 (en) 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040131676A1 (en) 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2006028342A1 (en) 2004-09-06 2006-03-16 Biosynergen, Inc. A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same
EP1819334A1 (en) 2004-11-19 2007-08-22 Shiva Biomedical, LLC Methods of treating erythropoietin-resistance
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
WO2007019153A2 (en) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
US20090124623A1 (en) 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CA2669935A1 (en) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
RU2009131454A (ru) 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
MX2007011927A (es) 2007-09-26 2009-03-26 World Trade Imp Export Wtie Ag Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.
US20100311756A1 (en) 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
AR082022A1 (es) 2010-06-25 2012-11-07 Teijin Pharma Ltd Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal
NZ605562A (en) 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use
JP5978216B2 (ja) * 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法

Also Published As

Publication number Publication date
US9107912B2 (en) 2015-08-18
AU2011299153B2 (en) 2014-10-30
CA2812034A1 (en) 2012-03-15
JP2013539747A (ja) 2013-10-28
EP2613780B1 (en) 2014-11-12
KR20130097775A (ko) 2013-09-03
WO2012033941A1 (en) 2012-03-15
BR112013005792A8 (pt) 2018-05-08
AU2011299153A1 (en) 2013-03-07
RU2013109380A (ru) 2014-10-20
CN103298466A (zh) 2013-09-11
US20120065236A1 (en) 2012-03-15
KR101797936B1 (ko) 2017-11-15
BR112013005792A2 (pt) 2016-05-03
CA2812034C (en) 2018-10-23
ES2532210T3 (es) 2015-03-25
CN103298466B (zh) 2015-11-25
HK1189170A1 (zh) 2014-05-30
EP2613780A1 (en) 2013-07-17
US8372872B2 (en) 2013-02-12
US20120065207A1 (en) 2012-03-15
US20120065215A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
CA2812034C (en) Methods for concomitant treatment of theophylline and febuxostat
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
JP7697885B2 (ja) 化合物の製剤およびそれらの使用
TW201136916A (en) New uses
CN113557022A (zh) 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
JP2023548600A (ja) 低グレード神経膠腫を処置するためのｒａｆインヒビター
CN104602686A (zh) 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
TWI901895B (zh) 一種包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－甲酸的醫藥組成物
WO2011141419A1 (en) Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
WO2004009118A1 (ja) 糖尿病の発症予防薬
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
HK1189170B (en) Methods for concomitant treatment of theophylline and febuxostat
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
US20130317034A1 (en) Combination therapy for treating diabetes
JP5559696B2 (ja) 糖尿病性腎症の治療剤
US20130116291A1 (en) Association of xanthine oxidase inhibitors and statins and use thereof
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
TW200816995A (en) Pharmaceutical composition containing insulin sensitizers
JP2010222347A (ja) Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
WO2007069669A1 (ja) アディポネクチン産生を増強する医薬組成物
WO2000028984A1 (fr) Remedes agissant contre un trouble fonctionnel du tractus digestif

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140905

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160725

R150 Certificate of patent or registration of utility model

Ref document number: 5978216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250